APPLIED PHARMACEUTICAL TOXICOLOGY 2021 - Virtual Event

Save the Date for 2021!

May 10 - 11, 2021 Discovery Toxicology Workshop

May 18-19, 2021 Development Toxicology Workshop

Plenary Speakers for 2021

Laura Dill Morton, DVM, PhD

Director of Toxicology at Aclairo Pharmaceutical Development Group, Inc.

Engaging CBER on Preclinical Gene Therapy Projects - a Consultant's Perspective

Daniel Nomura, PhD

Professor of Chemical Biology, University of California at Berkeley

Reimagining Druggability using Chemoproteomic Platforms

Lisa Plitnick, PhD

Distinguished Scientist, Merck

Discovery and Development of Vaccines and Worldwide Regulatory Experience

Jacinta Shenton, PhD

Senior Scientific Director, Nonclinical Safety Therapeutic Area Lead Immuno-Oncology, Janssen

TBA

Speakers Confirmed for 2021

		Ahmet Hoke, MD, PhD Professor of Neurology and Neuroscience, Director of Neuromuscular Division, Johns Hopkins School of Medicine Title TBA		Christopher Aluise, PhD Senior Research Scientist, Toxicology, Eli Lilly and Company Title TBA

		Lauren E. Black, PhD Distinguished Scientist, Scientific Advisory Services, Charles River Laboratories Adapting Traditional Tox Strategy to Patients with High Risk, Genetic Disorders: Do Regulations Speak to the Heart of the Issue?		Christopher Brynczka, PhD, DABT Senior Principal Scientist, Merck STINg in IO Space Immunomodulators

		Juliane Gust, MD, PhD Center for Integrative Brain Research, Seattle Children's Hospital CAR T Neurotoxicity: Translational Insights		Tomomi Kiyota, PhD Senior Scientist, Investigative Toxicology, Genentech Antibiotic-Induced Renal Toxicity Evaluation Using a Proximal Tubule On-a-Chip

		Hervé Lebrec, PharmD, PhD, DABT Scientific Director, Translational Safety & Bioanalytical Services, Amgen Experience with Nonhuman Primate Models in CAR-T Therapy Nonclinical Safety Assessment		Kerry Jo Lee, MD Acting Associate Director for Rare Diseases, OND/CDER/FDA Regulatory Challenges and Considerations in Rare Disease Drug Development

		Changhua Ji, MD, PhD Associate Research Fellow, Pfizer Nonclinical Evaluation of CD3 Bispecific Antibodies		Matt Liu, PhD, DABT Fellow, Toxicology, Regeneron Pharmaceuticals, Inc. Rapid Development of REGN-COV2, an Anti-Spike Antibody Cocktail for Treatment and Prevention of COVID-19

		Lisa Mangus, DVM, PhD, DACVP Assistant Professor, Dept. of Molecular & Comparative Pathobiology, Johns Hopkins School of Medicine Intra-Epidermal Nerve Fiber Analysis: a Sensitive, Clinically-Relevant Tool for Assessing Sensory Nerve Damage in Animal Models		Kim Maratea, DVM, PhD, DACVP Associate Director Pathology, Oncology Safety, AstraZeneca Early Assessment of Bone Marrow Toxicity in Immunodeficient Mice

		John McNulty, PhD Senior Director/Drug Safety Therapeutic Lead - Rare Disease, Takeda Nonclinical Safety Considerations in the Development of Treatments for Rare Diseases at Shire		Scott Mittelstadt, PhD Director of Investigative Toxicology and Safety Pharmacology, AbbVie CiPA: Practical Applications in Discovery

		Suman Mukherjee, PhD Director, In Vivo PK and TK Group, Safety Assessment, Merck TBA		Lutz Mueller, PhD Distinguished Scientist - Project Leader, F. Hoffmann- La Roche Ltd. Evrysdi - Spinal Muscular Atrophy

		Michael Polydefkis, MD MHS Professor, Neurology, Johns Hopkins University School of Medicine TBA		Chandra Saravanan, PhD Senior Veterinary Pathologist, Novartis Institutes for BioMedical Research Title TBA

		Nicola Stagg, PhD, DABT Senior Scientist/Toxicologist, Genentech Title TBA		Jonathan Stauber, PhD Director, ImaBiotech Role of Drug Exposure Quantification for Safety and Efficacy Evaluation in Non Clinical and Clinical Trials

		Richard Stebbings, PhD Director Oncology ICA Safety Sciences & Discovery, AstraZeneca COVID19 Vaccine AstraZeneca: Mission Impossible EUA		Jessica Sutherland, PhD, DABT Senior Director, Toxicology, Alnylam Pharmaceuticals The Nonclinical Safety Profile of ONPATTRO® (patisiran), a First-in Class RNAi Therapeutic for the Treatment of Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis)

		John Vahle, PhD, DABT Senior Research Fellow, Eli Lilly Title TBA		Andy Vo, PhD Senior Scientist - Computational Toxicology, AbbVie Integrating a Big Toxicity Data Framework to Better Evaluate Drug Safety

		Matt Wagoner, PhD Director of Investigative Toxicology, Takeda Pharmaceuticals Title TBA		Larry Whiteley, DVM Senior Director, Pfizer Gene Therapy Non-clinical to Clinical Translation
		Javier Waksman, MD, DABT, FAACT Vice President, Head of Drug Safety, Sangamo Therapeutics, Inc. Hepatotoxicity Associated with AAV-based Gene Therapy: Evaluation, Mechanism, and Treatment		Ahmet Hoke, Professor at Johns Hopkins School of Medicine Title TBA